CBF changes and cerebral energy metabolism during hypervolemia, hemodilution, and hypertension therapy in patients with poor-grade subarachnoid hemorrhage.

and hemodilution therapy cerebral blood flow cerebral microdialysis delayed cerebral ischemia hypertension hypervolemia subarachnoid hemorrhage triple-H vascular disorders xenon CT

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
10 Jan 2020
Historique:
received: 10 10 2019
accepted: 05 11 2019
medline: 11 1 2020
pubmed: 11 1 2020
entrez: 11 1 2020
Statut: epublish

Résumé

Despite the multifactorial pathogenesis of delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH), augmentation of cerebral blood flow (CBF) is still considered essential in the clinical management of DCI. The aim of this prospective observational study was to investigate cerebral metabolic changes in relation to CBF during therapeutic hypervolemia, hemodilution, and hypertension (HHH) therapy in poor-grade SAH patients with DCI. CBF was assessed by bedside xenon-enhanced CT at days 0-3, 4-7, and 8-12, and the cerebral metabolic state by cerebral microdialysis (CMD), analyzing glucose, lactate, pyruvate, and glutamate hourly. At clinical suspicion of DCI, HHH therapy was instituted for 5 days. CBF measurements and CMD data at baseline and during HHH therapy were required for study inclusion. Non-DCI patients with measurements in corresponding time windows were included as a reference group. In DCI patients receiving HHH therapy (n = 12), global cortical CBF increased from 30.4 ml/100 g/min (IQR 25.1-33.8 ml/100 g/min) to 38.4 ml/100 g/min (IQR 34.2-46.1 ml/100 g/min; p = 0.006). The energy metabolic CMD parameters stayed statistically unchanged with a lactate/pyruvate (L/P) ratio of 26.9 (IQR 22.9-48.5) at baseline and 31.6 (IQR 22.4-35.7) during HHH. Categorized by energy metabolic patterns during HHH, no patient had severe ischemia, 8 showed derangement corresponding to mitochondrial dysfunction, and 4 were normal. The reference group of non-DCI patients (n = 11) had higher CBF and lower L/P ratios at baseline with no change over time, and the metabolic pattern was normal in all these patients. Global and regional CBF improved and the cerebral energy metabolic CMD parameters stayed statistically unchanged during HHH therapy in DCI patients. None of the patients developed metabolic signs of severe ischemia, but a disturbed energy metabolic pattern was a common occurrence, possibly explained by mitochondrial dysfunction despite improved microcirculation.

Identifiants

pubmed: 31923897
doi: 10.3171/2019.11.JNS192759
pii: 2019.11.JNS192759
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-564

Auteurs

Henrik Engquist (H)

Departments of1Neuroscience/Neurosurgery and.
2Surgical Sciences/Anesthesia and Intensive Care, Uppsala University, Uppsala, Sweden.

Anders Lewén (A)

Departments of1Neuroscience/Neurosurgery and.

Lars Hillered (L)

Departments of1Neuroscience/Neurosurgery and.

Elisabeth Ronne-Engström (E)

Departments of1Neuroscience/Neurosurgery and.

Pelle Nilsson (P)

Departments of1Neuroscience/Neurosurgery and.

Per Enblad (P)

Departments of1Neuroscience/Neurosurgery and.

Elham Rostami (E)

Departments of1Neuroscience/Neurosurgery and.

Classifications MeSH